Ying Zhu, Vice President of CMC Development
Professional Overview
Ying Zhu is an experienced biopharmaceutical executive with a proven track record in technical operations and CMC (Chemistry, Manufacturing, and Controls) development. As the Vice President of CMC Development at Immune-Onc Therapeutics, she is responsible for leading the company's process and product development efforts, ensuring the successful advancement of novel immunotherapies from the lab to the clinic.
Experience Summary
Current Role
As the Vice President of CMC Development at Immune-Onc Therapeutics since 2021, Ying Zhu is responsible for overseeing all aspects of the company's CMC operations, including process development, analytical method development, and technology transfer. She has played a key role in streamlining the company's manufacturing processes, resulting in improved efficiency and cost-effectiveness. Under her leadership, Immune-Onc has successfully progressed multiple clinical candidates, contributing to the company's growth and pipeline advancement.
Career Progression
Prior to her current role, Ying served as the Executive Director of Technical Operations at Ankasa Regenerative Therapeutics, where she was instrumental in establishing the company's manufacturing capabilities and supporting the development of their regenerative medicine products. She has also held various senior-level positions at leading biopharmaceutical companies, including Associate Director of Cell Culture at Boehringer Ingelheim, Senior Scientist at Abbott Biotherapeutics, and Staff Scientist at PDL BioPharma. Throughout her career, Ying has demonstrated a strong technical expertise in cell line development, process optimization, and analytical method validation, contributing to the successful development and commercialization of several biotherapeutic products.
Academic Background
Ying Zhu holds a Ph.D. in Biochemical Engineering from the University of California, Berkeley, where she specialized in the development of novel bioreactor systems and optimization of mammalian cell culture processes. Her research work has been published in several peer-reviewed journals, and she has presented at numerous industry conferences, showcasing her technical expertise and thought leadership.
Areas of Expertise
- Biopharmaceutical process development and optimization
- Cell line engineering and process intensification
- Analytical method development and validation
- CMC strategy and regulatory compliance
- Cross-functional team leadership and project management
Professional Impact
Ying Zhu's contributions have had a significant impact on the biopharmaceutical industry. Her work has led to the successful advancement of multiple drug candidates, including the development of a novel antibody-drug conjugate for the treatment of solid tumors, which is currently in Phase II clinical trials. Ying's expertise in technical operations and her ability to drive innovative solutions have been instrumental in accelerating the development of Immune-Onc's pipeline and positioning the company as a leader in the field of immuno-oncology.
Conclusion
With her exceptional technical expertise, strategic vision, and proven track record of success, Ying Zhu is poised to continue driving innovation and progress in the biopharmaceutical industry. As the Vice President of CMC Development at Immune-Onc Therapeutics, she is committed to advancing the company's novel immunotherapies and improving patient outcomes.
